
Stacey Nee Macfarlane
Examiner (ID: 15384, Phone: (571)270-3057 , Office: P/1649 )
| Most Active Art Unit | 1649 |
| Art Unit(s) | 1649, 1609, 1675 |
| Total Applications | 1043 |
| Issued Applications | 437 |
| Pending Applications | 124 |
| Abandoned Applications | 499 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 18659015
[patent_doc_number] => 20230305016
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-09-28
[patent_title] => TEST KIT AND METHOD OF DETERMINING TRYPTOPHAN IN EXTRACTS OF FAECAL SAMPLES
[patent_app_type] => utility
[patent_app_number] => 18/024210
[patent_app_country] => US
[patent_app_date] => 2021-09-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9293
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18024210
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/024210 | TEST KIT AND METHOD OF DETERMINING TRYPTOPHAN IN EXTRACTS OF FAECAL SAMPLES | Sep 1, 2021 | Pending |
Array
(
[id] => 17398286
[patent_doc_number] => 20220040376
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-02-10
[patent_title] => DECELLULARIZED NERVE ALLOGRAFTS
[patent_app_type] => utility
[patent_app_number] => 17/411787
[patent_app_country] => US
[patent_app_date] => 2021-08-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5857
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 85
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17411787
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/411787 | DECELLULARIZED NERVE ALLOGRAFTS | Aug 24, 2021 | Abandoned |
Array
(
[id] => 17460286
[patent_doc_number] => 20220073591
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-03-10
[patent_title] => RECOMBINANT CLUSTERIN AND USE THEREOF IN THE TREATMENT AND PREVENTION OF DISEASE
[patent_app_type] => utility
[patent_app_number] => 17/406051
[patent_app_country] => US
[patent_app_date] => 2021-08-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14365
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17406051
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/406051 | RECOMBINANT CLUSTERIN AND USE THEREOF IN THE TREATMENT AND PREVENTION OF DISEASE | Aug 17, 2021 | Abandoned |
Array
(
[id] => 17548181
[patent_doc_number] => 20220119522
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-04-21
[patent_title] => ANTI-TREM2 ANTIBODIES AND METHODS OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/402986
[patent_app_country] => US
[patent_app_date] => 2021-08-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 57470
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17402986
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/402986 | Anti-TREM2 antibodies and methods of use thereof | Aug 15, 2021 | Issued |
Array
(
[id] => 18694014
[patent_doc_number] => 20230324418
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-12
[patent_title] => METHOD FOR DIAGNOSING AND TREATING COGNITIVE IMPAIRMENT AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/021211
[patent_app_country] => US
[patent_app_date] => 2021-08-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 3261
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -5
[patent_words_short_claim] => 42
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18021211
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/021211 | METHOD FOR DIAGNOSING AND TREATING COGNITIVE IMPAIRMENT AND USE THEREOF | Aug 12, 2021 | Pending |
Array
(
[id] => 17369992
[patent_doc_number] => 20220025044
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-01-27
[patent_title] => ANTIBODY WHICH BINDS TO MYELIN OLIGODENDROCYTE GLYCOPROTEIN
[patent_app_type] => utility
[patent_app_number] => 17/399354
[patent_app_country] => US
[patent_app_date] => 2021-08-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 50425
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 949
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17399354
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/399354 | ANTIBODY WHICH BINDS TO MYELIN OLIGODENDROCYTE GLYCOPROTEIN | Aug 10, 2021 | Abandoned |
Array
(
[id] => 17256823
[patent_doc_number] => 20210369808
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-02
[patent_title] => CHEMICAL REPROGRAMMING OF HUMAN GLIAL CELLS INTO NEURONS FOR BRAIN AND SPINAL CORD REPAIR
[patent_app_type] => utility
[patent_app_number] => 17/397927
[patent_app_country] => US
[patent_app_date] => 2021-08-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17004
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17397927
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/397927 | Chemical reprogramming of human glial cells into neurons for brain and spinal cord repair | Aug 8, 2021 | Issued |
Array
(
[id] => 18598414
[patent_doc_number] => 20230273213
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-31
[patent_title] => PEPTIDE DESIGN AND GALECTIN-3 INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 18/017841
[patent_app_country] => US
[patent_app_date] => 2021-08-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 31923
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -41
[patent_words_short_claim] => 25
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18017841
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/017841 | PEPTIDE DESIGN AND GALECTIN-3 INHIBITORS | Aug 1, 2021 | Pending |
Array
(
[id] => 17336034
[patent_doc_number] => 20220002365
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-01-06
[patent_title] => Bi-Functional Anti-Tau Polypeptides and Use Thereof
[patent_app_type] => utility
[patent_app_number] => 17/385252
[patent_app_country] => US
[patent_app_date] => 2021-07-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11523
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17385252
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/385252 | Bi-functional anti-tau polypeptides and use thereof | Jul 25, 2021 | Issued |
Array
(
[id] => 18196712
[patent_doc_number] => 20230050231
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-02-16
[patent_title] => Compositions and Methods for Modulating Kinase Activity
[patent_app_type] => utility
[patent_app_number] => 17/380704
[patent_app_country] => US
[patent_app_date] => 2021-07-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16960
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 138
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17380704
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/380704 | Compositions and methods for modulating kinase activity | Jul 19, 2021 | Issued |
Array
(
[id] => 19411794
[patent_doc_number] => 12077601
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-09-03
[patent_title] => Antibodies to ubiquitin C-terminal hydrolase L1 (UCH-L1) and glial fibrillary acidic protein (GFAP) and related methods
[patent_app_type] => utility
[patent_app_number] => 17/379739
[patent_app_country] => US
[patent_app_date] => 2021-07-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 98669
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 45
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17379739
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/379739 | Antibodies to ubiquitin C-terminal hydrolase L1 (UCH-L1) and glial fibrillary acidic protein (GFAP) and related methods | Jul 18, 2021 | Issued |
Array
(
[id] => 20067080
[patent_doc_number] => 20250205302
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-06-26
[patent_title] => COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEURODAMAGE
[patent_app_type] => utility
[patent_app_number] => 17/377487
[patent_app_country] => US
[patent_app_date] => 2021-07-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 43576
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 48
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17377487
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/377487 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEURODAMAGE | Jul 15, 2021 | Pending |
Array
(
[id] => 20143988
[patent_doc_number] => 12378315
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-08-05
[patent_title] => Anti-rabbit CD19 antibodies and methods of use
[patent_app_type] => utility
[patent_app_number] => 17/362126
[patent_app_country] => US
[patent_app_date] => 2021-06-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 11
[patent_figures_cnt] => 19
[patent_no_of_words] => 22343
[patent_no_of_claims] => 15
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 93
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17362126
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/362126 | Anti-rabbit CD19 antibodies and methods of use | Jun 28, 2021 | Issued |
Array
(
[id] => 17140088
[patent_doc_number] => 20210308099
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-10-07
[patent_title] => METHODS AND COMPOSITIONS FOR TREATMENT OF ALZHEIMER'S DISEASE AND OTHER NEURODEGENERATIVE DISORDERS
[patent_app_type] => utility
[patent_app_number] => 17/351410
[patent_app_country] => US
[patent_app_date] => 2021-06-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9241
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17351410
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/351410 | METHODS AND COMPOSITIONS FOR TREATMENT OF ALZHEIMER'S DISEASE AND OTHER NEURODEGENERATIVE DISORDERS | Jun 17, 2021 | Abandoned |
Array
(
[id] => 18538718
[patent_doc_number] => 20230243822
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-03
[patent_title] => MOLECULAR DISEASE PROFILE AND USE THEREOF FOR MONITORING AND TREATING RHEUMATAOID ARTHRITIS
[patent_app_type] => utility
[patent_app_number] => 18/003185
[patent_app_country] => US
[patent_app_date] => 2021-06-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19411
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 103
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18003185
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/003185 | MOLECULAR DISEASE PROFILE AND USE THEREOF FOR MONITORING AND TREATING RHEUMATAOID ARTHRITIS | Jun 14, 2021 | Pending |
Array
(
[id] => 17257313
[patent_doc_number] => 20210370298
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-02
[patent_title] => Microfluidic Device For Cell Separation And Uses Thereof
[patent_app_type] => utility
[patent_app_number] => 17/345451
[patent_app_country] => US
[patent_app_date] => 2021-06-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11666
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17345451
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/345451 | Microfluidic Device For Cell Separation And Uses Thereof | Jun 10, 2021 | Abandoned |
Array
(
[id] => 17274824
[patent_doc_number] => 20210381022
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-09
[patent_title] => INTEGRATED DRUG DISCOVERY PLATFORM FOR INBORN ERROR OF METABOLISM DISORDERS
[patent_app_type] => utility
[patent_app_number] => 17/345248
[patent_app_country] => US
[patent_app_date] => 2021-06-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 56958
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 97
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17345248
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/345248 | INTEGRATED DRUG DISCOVERY PLATFORM FOR INBORN ERROR OF METABOLISM DISORDERS | Jun 10, 2021 | Pending |
Array
(
[id] => 17110073
[patent_doc_number] => 20210290670
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-09-23
[patent_title] => METHODS OF TREATING OR PREVENTING ALZHEIMER'S DISEASE AND ASSOCIATED CONDITIONS
[patent_app_type] => utility
[patent_app_number] => 17/338305
[patent_app_country] => US
[patent_app_date] => 2021-06-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22412
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -31
[patent_words_short_claim] => 52
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17338305
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/338305 | Methods of treating or preventing alzheimer's disease and associated conditions | Jun 2, 2021 | Issued |
Array
(
[id] => 17080619
[patent_doc_number] => 20210275625
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-09-09
[patent_title] => METHOD OF MODULATING THE CONCENTRATION OF PROTEINS IN CEREBROSPINAL FLUID
[patent_app_type] => utility
[patent_app_number] => 17/329685
[patent_app_country] => US
[patent_app_date] => 2021-05-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5574
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17329685
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/329685 | METHOD OF MODULATING THE CONCENTRATION OF PROTEINS IN CEREBROSPINAL FLUID | May 24, 2021 | Abandoned |
Array
(
[id] => 18434454
[patent_doc_number] => 20230181748
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-15
[patent_title] => MEANS AND METHODS FOR THE TREATMENT OF PATHOLOGICAL AGGREGATION
[patent_app_type] => utility
[patent_app_number] => 17/925160
[patent_app_country] => US
[patent_app_date] => 2021-05-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 29745
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17925160
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/925160 | MEANS AND METHODS FOR THE TREATMENT OF PATHOLOGICAL AGGREGATION | May 16, 2021 | Abandoned |